Chronic wound infections: The role of Pseudomonas aeruginosa and Staphylococcus aureus

Expert Review of Anti-Infective Therapy

Volumn 13, Issue 5, 2015, Pages 605-613

  Serra, Raffaele ^a   Grande, Raffaele ^a   Butrico, Lucia ^a   Rossi, Alessio ^b   Settimio, Ugo Francesco ^a   Caroleo, Benedetto ^a   Amato, Bruno ^a,c   Gallelli, Luca ^a   De Franciscis, Stefano ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antibiotics; Chronic leg ulcers; Chronic wounds; Pseudomonas aeruginosa; Staphylococcus aureus

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFAZOLIN; CEFTAROLINE; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; ERTAPENEM; LEVOFLOXACIN; LINEZOLID; MATRIX METALLOPROTEINASE; MEROPENEM; METICILLIN; MOXIFLOXACIN; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATION; CHRONIC WOUND; COMORBIDITY; DECUBITUS; DIABETIC FOOT; DRUG EFFICACY; DRUG SAFETY; HUMAN; MIXED INFECTION; NONHUMAN; PSEUDOMONAS AERUGINOSA; REVIEW; SKIN FLORA; SKIN ULCER; STAPHYLOCOCCUS AUREUS; ULCER; WOUND HEALING; WOUND INFECTION; LEG ULCER; MICROBIOLOGY; PATHOGENICITY; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

HUMANS; LEG ULCER; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; WOUND INFECTION;

EID: 84930192741     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2015.1023291     Document Type: Review

References (128)

1. Gjødsbøl K, Christensen JJ, Karlsmark T, et al. Multiple bacterial species reside in chronic wounds: a longitudinal study. Int Wound J 2006;3(3):225-31
2. Serra R, Grande R, Butrico L, et al. Skin grafting and topical application of platelet gel in the treatment of vascular lower extremity ulcers. Acta Phlebol 2014;15(3): 129-36
3. Skerritt L, Moore Z. The prevalence, aetiology and management of wounds in a community care area in Ireland. Br J Community Nurs 2014(Suppl):S11-17
4. Markova A, Mostow EN. US skin disease assessment: ulcer and wound care. Dermatol Clin 2012;30(1):107-11; ix
5. Gottrup F. A specialized wound-healing center concept: importance of a multidisciplinary department structure and surgical treatment facilities in the treatment of chronic wounds. Am J Surg 2004; 187(5A):38S-43S
6. Pannier F, Rabe E. Differential diagnosis of leg ulcers. Phlebology 2013;28(Suppl 1): 55-60
7. Wang T, Feng Y, Sun H, et al. miR-21 regulates skin wound healing by targeting multiple aspects of the healing process. Am J Pathol 2012;181(6):1911-20
8. Johnson KE, Wilgus TA. Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. Adv Wound Care (New Rochelle) 2014;3(10):647-61
9. Serra R, Buffone G, Costanzo G, et al. Altered Metalloproteinase-9 expression as the least common denominator between Varicocele, Inguinal Hernia and Chronic Venous Disorders. Ann Vasc Surg 2014; 28(3):705-9
10. Amato B, Coretti G, Compagna R, et al. Role of matrix metalloproteinases in non-healing venous ulcers. Int Wound J 2013. [Epub ahead of print]
11. Serra R, Buffone G, Falcone D, et al. Chronic venous leg ulcers are associated with high levels of metalloproteinases-9 and neutrophil gelatinase-associated lipocalin. Wound Repair Regen 2013;21(3):395-401
12. Serra R, Grande R, Buffone G, et al. The effects of minocycline on extracellular matrix in patients with chronic venous leg ulcers. Act Phlebol 2013;14:99-107
13. Serra R, Grande R, Butrico L, et al. Effects of a new nutraceutical substance on clinical and molecular parameters in patients with chronic venous ulceration. Int Wound J 2014. [Epub ahead of print]
14. Serra R, Gallelli L, Buffone G, et al. Doxycycline speeds up healing of chronic venous ulcers. Int Wound J 2013.
15. Serra R, Gallelli L, Conti A, et al. The effects of Sulodexide on both clinical and molecular parameters in patients with mixed arterial and ulcers of lower limbs. Drug Des Devel Ther 2014;8:519-527
16. Serra R, Grande R, Buffone G, et al. Extracellular matrix assessment of infected chronic venous leg ulcers: role of metalloproteinases and inflammatory cytokines. Int Wound J 2014. [Epub ahead of print]
17. Kim BK, Lee YK, Park KY, et al. Analysis of multiple risk factors affecting the result of free flap transfer for necrotisingsoft tissue defects of the lower extremities in patients with type 2 diabetes mellitus. J Plast Reconstr Aesthet Surg 2014;67(5):624-8
18. Wysocki AB, Bhalla-Regev SK, Tierno PM Jr, et al. Proteolytic activity by multiple bacterial species isolated from chronic venous leg ulcers degrades matrix substrates. Biol Res Nurs 2013;15(4):407-15
19. Renner R, Sticherling M, Rüger R, Simon J. Persistence of bacteria like Pseudomonas aeruginosa in non-healing venous ulcers. Eur J Dermatol 2012;22(6):751-7
20. Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H. T opical silver for preventing wound infection. Cochrane Database Syst Rev 2010(3):CD006478
21. Nelson EA, O'Meara S, Golder S, DASIDU Steering Group. Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabet Med 2006;23(4):348-59
22. Chow I, Lemos EV, Einarson TR. Management and prevention of diabetic foot ulcers and infections: a health economic review. Pharmacoeconomics 2008; 26(12):1019-35
23. Fazli M, Bjarnsholt T, Kirketerp-Møller K, et al. Nonrandom distribution of Pseudomonas aeruginosa and Staphylococcus aureus in chronic wounds. J Clin Microbiol 2009;47(12):4084-9
24. Malic S, Hill KE, Hayes A, et al. Detection and identification of specific bacteria in wound biofilms using peptide nucleic acid fluorescent in situ hybridization (PNA FISH). Microbiology 2009;155(Pt 8): 2603-11
25. Forster AJ, Oake N, Roth V, et al. Patient-level factors associated with methicillin-resistant Staphylococcus aureus carriage at hospital admission: a systematic review. Am J Infect Control 2013;41(3): 214-20
26. Gilchrist B. Treating bacterial wound infection. Nurs Times 1994;90(50):55-6; 58
27. Schmidtchen A, Wolff H, Hansson C. Differential proteinase expression by Pseudomonas aeruginosa derived from chronic leg ulcers. Acta Derm Venereol 2001;81(6):406-9
28. Vatcheva-Dobrevska R, Mulet X, Ivanov I, et al. Molecular epidemiology and multidrug resistance mechanisms of Pseudomonas aeruginosa isolates from Bulgarian hospitals. Microb Drug Resist 2013;19(5):355-61
29. De Leon S, Clinton A, Fowler H, et al. Synergistic Interactions of pseudomonas aeruginosa and staphylococcus aureus in an in vitro wound Model. Infect Immun 2014; 82(11):4718-28
30. Pastar I, Nusbaum AG, Gil J, et al. Interactions of Methicillin Resistant Staphylococcus aureus USA300 and Pseudomonas aeruginosa in Polymicrobial Wound Infection. PLoS One 2013;8(2): 1-11
31. Percival SL, Emanuel C, Cutting KF, Williams DW. Microbiology of the skin and the role of biofilms in infection. Int Wound J 2012;9:14-32
32. Christensen GJ, Brüggemann H. Bacterial skin commensals and their role as host guardians. Benef Microbes 2014;5(2): 201-15
33. Tuazon CU. Skin and skin structure infections in the patient at risk: carrier state of Staphylococcus aureus. Am J Med 1984; 76(5A):166-71
34. Hannigan GD, Grice EA. Microbial ecology of the skin in the era of metagenomics and molecular microbiology. Cold Spring Harb Perspect Med 2013;3(12):a015362
35. Nizet V, Ohtake T, Lauth X, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 2001;414:454-7
36. Wanke I, Steffen H, Christ C, et al. Skin commensals amplify the innate immune response to pathogens by activation of distinct signaling pathways. J Invest Dermatol 2011;131(2):382-90
37. Wang G. Human antimicrobial peptides and proteins. Pharmaceuticals (Basel) 2014; 7(5):545-94
38. Schittek B. The antimicrobial skin barrier in patients with atopic dermatitis. Curr Probl Dermatol 2011;41:54-67
39. Chaiwarith R, Pacharasupal P, Sirisanthana T. Epidemiology, clinical characteristics and treatment outcomes of healthcare-associated methicillin-resistant Staphylococcus aureus BLOODSTREAM infections at Chiang Mai University Hospital: a retrospective study. Southeast Asian J Trop Med Public Health 2014; 45(4):897-905
40. Truong-Bolduc QC, Villet RA, Estabrooks ZA, Hooper DC. Native efflux pumps contribute resistance to antimicrobials of skin and the ability of Staphylococcus aureus to colonize skin. J Infect Dis 2014;209(9):1485-93
41. Coates R, Moran J, Horsburgh MJ. Staphylococci: colonizers and pathogens of human skin. Future Microbiol 2014;9(1): 75-91
42. Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen 2003;11:S1-28
43. Fedtke I, Gotz F, Peschel A. Bacterial evasion of innate host defences: the Staphylococcus aureus lesson. Int J Med Microbiol 2004;294:189-94
44. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339(8):520-32
45. Daum RS, Spellberg B. Progress toward a staphylococcus aureus vaccine. Clin Infect Dis 2012;54(4):560-7
46. Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol 2005;3: 948-58
47. Jensen PØ, Bjarnsholt T, Phipps R, et al. Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum sensing controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology 2007;153:1329-38
48. Amin AN, Cerceo EA, Deitelzweig SB, et al. Hospitalist perspective on the treatment of skin and soft tissue infections. Mayo Clin Proc 2014;89(10):1436-51
49. Costerton JW, Lewandowski Z, Caldwell DE, et al. Microbial biofilms. Annu Rev Microbiol 1995;49:711-45
50. Matsukawa M, Greenberg EP. Putative exopolysaccharide synthesis genes influence Pseudomonas aeruginosa biofilm development. J Bacteriol 2004;186:4449-56
51. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science 2002;295:1487
52. Vandenesch F, Naimi T, Enright MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003;9:978-84
53. Finck-Barbançon V, Duportail G, Meunier O, Colin DA. Pore formation by a two-component leukocidin from Staphylococcus aureus within the membrane of human polymorphonuclear leukocytes. Biochim Biophys Acta 1993;1182(3):275-82
54. Staali L, Monteil H, Colin DA. The staphylococcal pore-forming leukotoxins open Ca2+ channels in the membrane of human polymorphonuclear neutrophils. J Membr Biol 1998;162(3):209-16
55. Hammer C, Rath PM, Steinmann J, et al. Panton-Valentine leukocidin in patients with chronic wounds. Results from a clinical investigation in 100 patients. Hautarzt 2014;65(2):148-52
56. Berktold M, Grif K, Mäser M, et al. Genetic characterization of Panton-Valentine leukocidin-producing methicillin-resistant Staphylococcus aureus in Western Austria. Wien Klin Wochenschr 2012;124(19-20):709-15
57. Witte W, Strommenger B, Cuny C, et al. Methicillin-resistant Staphylococcus aureus containing the Panton-Valentine leucocidin gene in Germany in 2005 and 2006. J Antimicrob Chemother 2007;60(6):1258-63
58. Wilson M, Seymour R, Henderson B. Bacterial perturbation of cytokine networks. Infect Immun 1998;66:2401
59. Wolcott RD, Rhoads DD. A study of biofilm-based wound management in subjects with critical limb ischaemia. J Wound Care 2008;17(4):145-8; 150-2, 154-5
60. Wolcott R, Costerton JW, Raoult D, Cutler SJ. The polymicrobial nature of biofilm infection. Clin Microbiol Infect 2013;19(2):107-12
61. Halbert AR, Stacey MC, Rohr JB, Jopp-McKay A. The effect of bacterial colonization on venous ulcer healing. Australas J Dermatol 1992;33:75-80
62. Madsen SM, Westh H, Danielsen L, Rosdahl VT. Bacterial colonization and healing of venous leg ulcers. APMIS 1996;104:895-9
63. Høiby N, Bjarnsholt T, Moser C, ESCMID Study Group for Biofilms (ESGB) and Consulting External Expert Werner Zimmerli. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect 2015. [Epub ahead of print]
64. Dowd SE, Wolcott RD, Sun Y, et al. Polymicrobial nature of chronic diabetic foot ulcer biofilm infections determined using bacterial tag encoded FLX amplicon pyrosequencing (bTEFAP). PLoS One 2008;3(10):e3326
65. Baffoni M, Bessa LJ, Grande R, et al. Laser irradiation effect on Staphylococcus aureus and Pseudomonas aeruginosa biofilms isolated from venous leg ulcer. Int Wound J 2012;9(5):517-24
66. Ammons MC, Copie V. Mini-review: lactoferrin: a bioinspired, anti-biofilm therapeutic. Biofouling 2013;29(4):443-55
67. Haji Zaine N, Burns J, Vicaretti M, et al. Characteristics of diabetic foot ulcers in Western Sydney, Australia. J Foot Ankle Res 2014;7(1):39
68. Arya AK, Tripathi R, Kumar S, Tripathi K. Recent advances on the association of apoptosis in chronic non healing diabetic wound. World J Diabetes 2014;5(6):756-62
69. Jenkins TC, Knepper BC, Jason Moore S, et al. Comparison of the microbiology and antibiotic treatment among diabetic and nondiabetic patients hospitalized for cellulitis or cutaneous abscess. J Hosp Med 2014;9(12):788-94
70. Nguyen KT, Seth AK, Hong SJ, et al. Deficient cytokine expression and neutrophil oxidative burst contribute to impaired cutaneous wound healing in diabetic biofilm-containing chronic wounds. Wound Repair Regen 2013;21(6):833-41
71. Oyibo SO, Jude EB, Tarawneh I, et al. The effects of ulcer size and site, patient's age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. Diabet Med 2001;18(2):133-8
72. Ammons MC. Anti-biofilm strategies and the need for innovations in wound care. Recent Pat Antiinfect Drug Discov 2010; 5(1):10-17
73. Percival SL, Hill KE, Williams DW, et al. A review of the scientific evidence for biofilms in wounds. Wound Repair Regen 2012;20(5):647-57
74. Malik A, Mohammad Z, Ahmad J. The diabetic foot infections: biofilms and antimicrobial resistance. Diabetes Metab Syndr 2013;7(2):101-7
75. Percival SL, Hill KE, Malic S, et al. Antimicrobial tolerance and the significance of persister cells in recalcitrant chronic wound biofilms. Wound Repair Regen 2011;19(1):1-9
76. Bjarnsholt T, Kirketerp-Møller K, Jensen PØ, et al. Why chronic wounds will not heal: a novel hypothesis. Wound Repair Regen 2008;16(1):2-10
77. Watters C, DeLeon K, Trivedi U, et al. Pseudomonas aeruginosa biofilms perturb wound resolution and antibiotic tolerance in diabetic mice. Med Microbiol Immunol 2013;202(2):131-41
78. Ortiz Balbuena J, Garćia Madero R, Segovia Gomez T, et al. Microbiology of pressure and vascular ulcer infections. Rev Esp Geriatr Gerontol 2015;50(1):5-8
79. Hansson C, Hoborn J, Moller A, Swanbeck G. The microbial flora in venous leg ulcers without clinical signs of infection. Repeated culture using a validated standardised microbiological technique. Acta Derm Venereol 1995;75(1):24-30
80. Lantis JC II, Gendics C. In vivo effect of sustained-release silver sulphadiazine foam on bioburden and wound closure in infected venous leg ulcers. J Wound Care 2011;20(2):90-6
81. O'Meara S, Al-Kurdi D, Ologun Y, et al. Antibiotics and antiseptics for venous leg ulcers. Cochrane Database Syst Rev 2014;1: CD003557
82. Serra R, Caroleo S, Buffone G, et al. Low serum albumin level as an independent risk factor for the onset of pressure ulcers in intensive care unit patients. Int Wound J 2014;11(5):550-3
83. Serra R, Grande R, Buffone G, et al. Albumin administration prevents the onset of pressure ulcers in intensive care unit patients. Int Wound J 2013
84. Stotts NA, Hunt TK. Pressure ulcers. Managing bacterial colonization and infection. Clin Geriatr Med 1997;13(3): 565-73
85. Lindholm C. Pressure ulcers and infection understanding clinical features. Ostomy Wound Manage 2003;49(5A Suppl):4-7
86. Gist S, Tio-Matos I, Falzgraf S, et al. Wound care in the geriatric client. Clin Interv Aging 2009;4:269-87
87. Braga IA, Pirett CC, Ribas RM, et al. Bacterial colonization of pressure ulcers: assessment of risk for bloodstream infection and impact on patient outcomes. J Hosp Infect 2013;83(4):314-20
88. Gandra S, Barysauskas CM, Mack DA, et al. Impact of contact precautions on falls pressure ulcers and transmission of MRSA and VRE in hospitalized patients. J Hosp Infect 2014;88(3):170-6
89. Miyoshi S, Shinoda S. Microbial metalloproteases and pathogenesis. Microbe Infect 2000;2:91-8
90. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69(3): 562-73
91. Geurts N, Opdenakker G, Van den Steen PE. Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. Pharmacol Ther 2012;133:257-9
92. Flores-Herrera H, Garcia-Lopez G, Díaz NF, et al. An experimental mixed bacterial infection induced differential secretion of proinflammatory cytokines (IL-1beta, TNFalpha) and proMMP-9 in human fetal membranes. Placenta 2012;33:271-7
93. Grayfer L, Hodgkinson JW, Belosevic M. Antimicrobial responses of teleost phagocytes and innate immune evasion strategies of intracellular bacteria. Dev Comp Immunol 2014;43:223-42
94. Maeda H. Role of microbial proteases in pathogenesis. Microbiol Immunol 1996; 40(10):685-99
95. Maeda H, Akaike T, Sakata Y, Maruo K. Role of bradykinin in microbial infection: enhancement of septicemia by microbial proteases and kinin. Agents Actions Suppl 1993;42:159-65
96. Maeda H, Yamamoto T. Pathogenic mechanisms induced by microbial proteases in microbial infections. Biol Chem Hoppe Seyler 1996;377(4):217-26
97. Golovkine G, Faudry E, Bouillot S, et al. VE-cadherin cleavage by LasB protease from Pseudomonas aeruginosa facilitates type III secretion system toxicity in endothelial cells. PLoS Pathog 2014;10(3):e1003939
98. Beaufort N, Corvazier E, Mlanaoindrou S, et al. Disruption of the endothelial barrier by proteases from the bacterial pathogen Pseudomonas aeruginosa: implication of matrilysis and receptor cleavage. PLoS One 2013;8(9):e75708
99. Cheng AG, De Dent AC, Schneewind O, Missiakas D. A play in four acts: staphylococcus aureus abscess formation. Trends Microbiol 2011;19(5):225-32
100. Nishifuji K, Sugai M, Amagai M. Staphylococcal exfoliative toxins: "molecular scissors" of bacteria that attack the cutaneous defense barrier in mammals. J Dermatol Sci 2008;49(1):21-31
101. Kim HK, Missiakas D, Schneewind O. Mouse models for infectious diseases caused by Staphylococcus aureus. J Immunol Methods 2014;410:88-99
102. Ladhani S. Understanding the mechanism of action of the exfoliative toxins of Staphylococcus aureus. FEMS Immunol Med Microbiol 2003;39(2):181-9
103. Wilke GA, Bubeck Wardenburg J. Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated cellular injury. Proc Natl Acad Sci USA 2010;107(30): 13473-8
104. Inoshima I, Inoshima N, Wilke GA, et al. A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nat Med 2011; 17(10):1310-14
105. Inoshima N, Wang Y, Bubeck Wardenburg J. Genetic requirement for ADAM10 in severe Staphylococcus aureus skin infection. J Invest Dermatol 2012;132(5):1513-16
106. Davies CE, Hill KE, Wilson MJ, et al. Use of 16S ribosomal DNA PCR and denaturing gradient gel electrophoresis for analysis of the microfloras of healing and nonhealing chronic venous leg ulcers. J Clin Microbiol 2004;42(8):3549-57
107. James GA, Swogger E, Wolcott R, et al. Biofilms in chronic wounds. Wound Repair Regen 2008;16(1):37-44
108. Kirketerp-Møller K, Jensen PØ, Fazli M, et al. Distribution, organization, and ecology of bacteria in chronic wounds. J Clin Microbiol 2008;46(8):2717-22
109. Gurusamy KS, Koti R, Toon CD, et al. Antibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non surgical wounds. Cochrane Database Syst Rev 2013;11:CD010427
110. Harkless L, Boghossian J, Pollak R, et al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg Infect (Larchmt) 2005;6(1):27-40
111. Körber A, Schmid EN, Buer J, et al. Bacterial colonization of chronic leg ulcers: current results compared with data 5 years ago in a specialized dermatology department. J Eur Acad Dermatol Venereol 2010;24(9):1017-25
112. Bessa LJ, Fazii P, Di Giulio M, Cellini L. Bacterial isolates from infected wounds and their antibiotic susceptibility pattern: some remarks about wound infection. Int Wound J 2013;12(1):47-52
113. Jacobsen F, Fisahn C, Sorkin M, et al. Efficacy of topically delivered moxifloxacin against wound infection by pseudomonas aeruginosa and methicillin-resistant staphylococcus aureus [down-pointing small open triangle]. Antimicrob Agents Chemother 2011;55(5):2325-34
114. Nathwani D, Raman G, Sulham K, et al. Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control 2014;3(1):32
115. Gallelli L, Ferreri G, Colosimo M, et al. Adverse drug reactions to antibiotics observed in two pulmonology divisions of Catanzaro, Italy: a six-year retrospective study. Pharmacol Res 2002;46(5):395-400
116. Palleria C, Di Paolo A, Giofrè C, et al. Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci 2013;18(7):601-10
117. Kim J, Ohtani H, Tsujimoto M, Sawada Y. Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents. Drug Metab Pharmacokinet 2009;24(2):167-74
118. van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002;324(7349): 1306-7
119. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007; 29(4):374-9
120. Nykamp DL, Blackmon CL, Schmidt PE, Roberson AG. QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine. Ann Pharmacother 2005;39(3):543-6
121. Siniscalchi A, Scaglione F, Sanzaro E, et al. Effects of phenobarbital and levetiracetam on PR and QTc intervals in patients with post-stroke seizure. Clin Drug Investig 2014;34(12):879-86
122. Ni W, Cai X, Liang B, et al. Effect of proton pump inhibitors on in vitro activity of tigecycline against several common clinical pathogens. PLoS One 2014;9(1): e86715
123. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014;59(2):e10-52
124. Deresinski S. Counterpoint: vancomycin Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 2007;44: 1543-8
125. Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 2007; 45(Suppl 3):S191-5
126. Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004;42:2398-402
127. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011;52(3): 285-92
128. Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007;45:601-8